2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Gene Editing, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Gene Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

2597 Midwest practice challenges in sickle cell disease (SCD) care with a focused look at rurality

Kristin Weeks, MD, PhD, Nicole Thomas, PhD, MS2, Alice A Gaughan, MS3, Ann Scheck McAlearney, ScD, MS4
1 The Ohio State University, columbus, Ohio, United States
2 The Ohio State University, columbus, Ohio, United States
3 The Ohio State University, columbus, Ohio, United States
4 The Ohio State University, columbus, Ohio, United States

Introduction

Sickle cell disease (SCD) is an inherited red blood cell disorder typically cared for at large centralized medical centers or hubs. In 2023, SCD care advanced with the approval of functionally curative gene therapy options primarily available at some of the large centralized medical centers or hubs. As there are fewer hubs per patient with SCD in the Midwest compared to other regions of the United States (US), we aimed to understand Midwest practice challenges with a special focus on understanding the impact of rurality on accessing new functionally curative gene therapy.

Methods

Using a mixed method approach, we recruited all SCD-focused hematologists practicing in 5 Midwest states to be interviewed over the telephone to improve our understanding of their perspectives on challenges in their practices and rural care delivery. Recruitment to the interview study stopped when saturation of themes was reached. Interviews were recorded, transcribed, and analyzed in a team-based approach utilizing inductive and deductive methods. Then, we recruited all SCD-focused hematologists practicing in the 11 Midwest states to complete a Qualtrics-based, electronic survey. Recruitment closed after 2 months, at which time 44 of the 91 (i.e., 48% response rate) SCD-focused hematologists in the Midwest had enrolled in our study.

Results

Interviewed SCD-focused hematologists described practice challenges of inadequate clinical space (example quote: “we have enough providers to see all the patients, but we just physically don't have the space to see them”), disjointed resources (example quote: “Our clinic is away from other specialties that they [the patients with SCD] need to see for their disease management like neurology or cardiovascular”), and a lack of multimodal pain management partnerships (example quote: “It has been extremely difficult to find partners in palliative care medicine and chronic pain who are willing to partner with us specifically for sickle cell care”). These findings were quantified in surveys with around one-third of SCD-focused hematologists reporting these challenges including limited access to: appropriate length timeslots for appointments (25%), nonpharmacologic pain management partners (30%), mental health resources (30%), sufficient SCD-focused providers (30%), and sufficient clinic space (34%).

Fourteen percent of SCD-focused hematologists perceived the majority of their patients were rural (i.e., compared to urban). Twenty seven percent of SCD-focused hematologists reported participating in an outreach clinic and 36% reported participating in the training of a smaller healthcare center. Seventy percent utilized telemedicine for some care appointments.

Interviewed SCD-focused hematologists perceived that rural patients with SCD had increased hardship accessing care due to being farther from SCD hubs and resources centers (example quotes: “[There is a burden related to] distance and the burden of driving” and “[there is a] lack of experience in their local community with the providers in management of sickle cell”). Surveyed SCD-focused hematologists reported that rural patients (compared to their urban counterparts) were more likely to have the feasibility of gene therapy limited by transportation issues (66%), less likely to receive a referral to gene therapy (55%), and less able to complete optimization prior to gene therapy (e.g., red blood cell exchange) (61%). This is juxtaposed by very few SCD-focused hematologists reporting a difference in comorbidities (11%), mistrust of new therapies (5%), as well as likely benefits of gene therapy (9%) based on rurality.  Notably, only 9% of surveyed SCD-focused hematologists reported they would personally limit referrals to gene therapy based on the distance to care.

Discussion

Further research is needed to address the systemic care delivery concerns identified. Efforts are needed to improve clinic resources for SCD-focused hematologists and multimodal pain management partnerships in the Midwest. Strategies to address the rural disadvantage in SCD care delivery, including comprehensive care and advanced therapy access, should be investigated. Strategies may include using “traveling trainees” (i.e., sending rural healthcare staff to assist with and learn from care at hubs), developing “networks of excellence” (i.e., engaging network partnerships), and developing multilevel interventions to address transportation barriers.

Kristin Weeks, MD, PhD: No relevant conflicts of interest to declare.